TY - JOUR
T1 - Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome
AU - Corti, Davide
AU - Passini, Nadia
AU - Lanzavecchia, Antonio
AU - Zambon, Maria
N1 - Publisher Copyright:
© 2016 King Saud Bin Abdulaziz University for Health Sciences.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - The last century has witnessed the emergence of several previously unknown viruses as life-threatening human pathogens. Several examples include HIV, Ebola, Lujo, and, most recently, the Middle East respiratory syndrome (MERS) and Ebola. In this study, we describe a method for the swift generation of a human-derived monoclonal antibody, known as LCA60, as a treatment for MERS infections. LCA60 antibody was generated using the Cellclone Technology from the immortalized B cells of a human donor recovering from MERS. Only four months were required from the initial screening of B cells to the development of a stable CHO cell line suitable for the production of clinical grade antibody, thereby delineating a rapid pathway for the development of antiviral therapies against emerging viruses. Currently, the LCA60 antibody is being considered for clinical development, which includes prophylaxis in individuals at risk and a treatment for severe MERS-CoV infections.
AB - The last century has witnessed the emergence of several previously unknown viruses as life-threatening human pathogens. Several examples include HIV, Ebola, Lujo, and, most recently, the Middle East respiratory syndrome (MERS) and Ebola. In this study, we describe a method for the swift generation of a human-derived monoclonal antibody, known as LCA60, as a treatment for MERS infections. LCA60 antibody was generated using the Cellclone Technology from the immortalized B cells of a human donor recovering from MERS. Only four months were required from the initial screening of B cells to the development of a stable CHO cell line suitable for the production of clinical grade antibody, thereby delineating a rapid pathway for the development of antiviral therapies against emerging viruses. Currently, the LCA60 antibody is being considered for clinical development, which includes prophylaxis in individuals at risk and a treatment for severe MERS-CoV infections.
UR - http://www.scopus.com/inward/record.url?scp=84963799673&partnerID=8YFLogxK
U2 - 10.1016/j.jiph.2016.04.003
DO - 10.1016/j.jiph.2016.04.003
M3 - Article
C2 - 27102927
AN - SCOPUS:84963799673
SN - 1876-0341
VL - 9
SP - 231
EP - 235
JO - Journal of Infection and Public Health
JF - Journal of Infection and Public Health
IS - 3
ER -
